Effect of Molsidomine on Spontaneous Ventricular Fibrillation following Myocardial Ischemia and Reperfusion in the Dog

  • P. A. Martorana
  • A. M. Mogilev
  • B. Kettenbach
  • R.-E. Nitz


The effect of the novel antianginal agent molsidomine on the incidence of spontaneous ventricular fibrillation during myocardial ischemia and reperfusion was investigated in the anesthetized dog. Molsidomine was administered as an intravenous bolus at the dose of 0.05 mg/kg. Twenty minutes later, the left anterior descending coronary artery was occluded for 90 min. During the occlusion period, molsidomine was given as a continuous intravenous infusion at the dose of 0.5 μg/kg per ml per min. After release of the occlusion, the animals that survived were monitored for another 30 min. Control animals received saline. In the control animals, coronary occlusion was accompanied by an increase in heart rate, heart contractility, left ventricular end-diastolic pressure, and blood pressure as well as by ventricular arrhythmias. Molsidomine either abolished or reduced both hemodynamic and electrical changes. During the reperfusion period, 10 out of 12 control animals died, and the deaths were from ventricular fibrillation; one out of eight molsidomine-treated animals also died of ventricular fibrillation. It is postulated that the protective effect of molsidomine rests on its hemodynamic effects resulting in a shift in blood flow toward the ischemic zones and, consequently, in an increase in ventricular electrical stability.


Ventricular Fibrillation Hemodynamic Effect Coronary Occlusion Left Ventricular Pressure Continuous Intravenous Infusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Berdeaux, A., Tato, F., Ho, S., Boissier, J. R., and Giudicelli, J. F. 1978. Molsidomine, debits coronaires regionaux et segment ST au niveau du myocarde sain et/ou ischemique chez le chien. J. Pharmacol. (Paris) 9:219–234.Google Scholar
  2. 2.
    Brooks, W. W., Verrier, R. L., and Lown, B. 1980. Protective effect of verapamil on vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion. Car-diovasc. Res. 14:295–302.CrossRefGoogle Scholar
  3. 3.
    Brown, A. M. 1967. Excitation of cardiac afferent sympathetic nerve fibres during myocardial ischemia. J. Physiol. (Lond.) 190:35–53.Google Scholar
  4. 4.
    Bussmann, W. D., Neidel, K., and Kaltenbach, M. 1979. Wirkung von Molsidomin auf Hämodynamik und Ischämie bei Patienten mit frischem Herzinfarkt. In: W. Lochner and F. Bender (eds.), Molsidomin, Neue Aspekte in der Therapie der ischämischen Herzerkrankung, pp. 100–104. Urban & Schwarzenberg, Munich.Google Scholar
  5. 5.
    Corbalan, R., Verrier, R. L., and Lown, B. 1976. Differing mechanisms for ventricular vulnerability during coronary artery occlusion and release. Am. Heart J. 92:223–230.PubMedCrossRefGoogle Scholar
  6. 6.
    Fiedler, V. B., and Scholtholt, J. 1978. Hemodynamic effects of molsidomine. Arzneim. Forsch. 9:1605–1612.Google Scholar
  7. 7.
    Fleck, E., Dirschinger, J., and Rudolph, W. 1979. Hämodynamische Wirkungen von Molsidomin bei koronarer Herzerkrankung. Herz 4:285–292.PubMedGoogle Scholar
  8. 8.
    Grund, E., Müller-Rucholtz, E. R., and Lapp, E. R., Lösch, H. M., and Lochner, W. 1978. Comparative study of nitroglycerin and molsidomine. Effects of the integrated systemic venous bed and the arterial pressure in dogs. Arzneim. Forsch. 9:1624–1628.Google Scholar
  9. 9.
    Hashimoto, K., Taira, N., Hirata, M., and Kokubun, M. 1971. The mode of hypotensive action of newly synthesized sydnonimine derivatives. Arzneim. Forsch. 21:1329–1332.Google Scholar
  10. 10.
    Hearse, D. J. 1977. Reperfusion of ischemic myocardium. J. Mol. Cell. Cardiol. 9:607–616.Google Scholar
  11. 11.
    Holtz, J., Bassenge, E., and Kolin, A. 1978. Hemodynamic and myocardial effects of long lasting venodilatation in the conscious dog: Analysis of molsidomine in comparison with nitrates. Basic Res. Cardiol. 73:469–481.PubMedCrossRefGoogle Scholar
  12. 12.
    Karsch, K. R., Rentrop, K. P., Blanke, H., and Kreuzer, H. 1978. Hemodynamic effects of molsidomine. Eur. J. Clin. Pharmacol. 13:241–245.PubMedCrossRefGoogle Scholar
  13. 13.
    Kikuchi, K., Hirata, M., and Nagaoka, A. 1970. Hypotensive action of N-ethoxycarbonyl-3-morpholinosydnonimine, SIN-10. Jpn. J. Pharmacol. 20:102–115.PubMedCrossRefGoogle Scholar
  14. 14.
    Majid, P. A., DeFeyter, P. J. F., van der Wall, E. E., Warden, R., and Roos, J. P. 1980. Molsidomine in the treatment of patients with angina pectoris. Acute hemodynamic effects and clinical efficacy. N. Engl. J. Med. 302:1–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Malliani, A., Schwartz, P. J., and Zanchetti, A. 1969. A sympathetic reflex elicited by experimental coronary occlusion. Am. J. Physiol. 217:703–709.PubMedGoogle Scholar
  16. 16.
    Nayler, W. G. 1980. The pharmacological protection of the ischemic heart. The use of calcium and beta-adrenoceptor antagonists. In: Abstracts, VII European Congress of Cardiology, Paris, p. 242.Google Scholar
  17. 17.
    Ribeiro, L. G. T., DeBauche, T. L., Brandon, T. A., Reduto, L. A., Maroko, P. R., and Miller, R. R. 1980. Comparative effects of calcium antagonists on reactive hyperemia and ventricular arrhythmias during coronary artery reperfusion. In: Abstracts, VII European Congress of Cardiology, Paris, p. 242.Google Scholar
  18. 18.
    Scholtholt, J., Fiedler, V. B., and Keil, M. 1978. Die Wirkung von Molsidomin und Nitroglycerin auf die regionale Durchblutung des normalen und akutischämischen Myokards. Arzneim. Forsch. 28:1619–1624.Google Scholar
  19. 19.
    Scholtholt, J., Fiedler, V. B., and Keil, M. 1978. Die Wirkung von Molsidomin auf die regionale Verteilung des Herzminutenvolumens des narkotisierten Hundes. Arzneim. Forsch. 28:1612–1619.Google Scholar
  20. 20.
    Stockman, M. B., Verrier, R. L., and Lown, B. 1979. Effect of nitroglycerin on vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion. Am. J. Cardiol. 43:233–238.PubMedCrossRefGoogle Scholar
  21. 21.
    Surawicz, B. 1971. Ventricular fibrillation. Am. J. Cardiol. 28:268–287.PubMedCrossRefGoogle Scholar
  22. 22.
    Takenaka, F., Takeya, N., Ishihara, T., Inoue, S., Tsutsumi, E., Nakamura, R., Mitsufuji, Y., and Sumie, M. 1970. Effects of N-ethoxycarbonyl-3-morpholinosydnonimine (SIN-10) on cardiovascular system. Jpn. J. Pharmacol. 20:253–263.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • P. A. Martorana
    • 1
  • A. M. Mogilev
    • 1
  • B. Kettenbach
    • 1
  • R.-E. Nitz
    • 1
  1. 1.Department of Medical and Biological Research, Department of PharmacologyCassella AGFrankfurt/MainFederal Republic of Germany

Personalised recommendations